
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -3.92156862745 | 1.02 | 1.08 | 0.8 | 233308 | 0.95536377 | CS |
4 | -0.205 | -17.2995780591 | 1.185 | 1.22 | 0.8 | 215855 | 1.06566898 | CS |
12 | -0.1425 | -12.6948775056 | 1.1225 | 1.5 | 0.8 | 312910 | 1.1675227 | CS |
26 | -0.61 | -38.3647798742 | 1.59 | 2.5591 | 0.8 | 912170 | 1.54892074 | CS |
52 | 0.0394 | 4.18881564959 | 0.9406 | 5.01 | 0.51 | 1968125 | 2.83640312 | CS |
156 | -6.02 | -86 | 7 | 7.9799 | 0.51 | 1302471 | 2.83809811 | CS |
260 | -6.02 | -86 | 7 | 7.9799 | 0.51 | 1302471 | 2.83809811 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions